Latest Video Most Popular Video

Brett Favre visits Cramer

Mad Money host Jim Cramer receives a visit from future Hall-of-Fame QB for the Green Bay Packers, Brett Favre.

Sponsoring the Super Bowl

CNBC's Jane Wells takes a look at Super Bowl 50 sponsors in the Bay area.

Mad Money host Jim Cramer sits down with Rob Gronkowski of the New England Patriots just days for the big Super Bowl 50.

BRAFMAN FULL INTERVIEW

Former Turing Pharmaceuticals CEO Martin Shkreli was scheduled to testify to Congress today, but exercised his 5th Amendment right to not incriminate himself. Shkreli's lawyer Benjamin Brafman, explains his client's position.

Cramer explains the sudden flock to commodities

Mad Money host Jim Cramer explains the complicated relationship between the strength of the dollar and commodity stocks, and what it means to your portfolio.

5 divine dividend plays for you

CNBC's Dom Chu reviews the criteria for divine dividend stocks.

Dwight Clark explains 'The Catch'

Dwight Clark, former wide receiver for the San Francisco 49ers, explains what happened when he caught a pass from Joe Montana which sent the team to its first Super Bowl in 1982. It's been simply called, "The Catch."

Jim Cramer on Brafman's attempt: My breath is taken away

Martin Shkreli's Attorney Benjamin Brafman attempted to address Congress in a hearing on drug price hikes, in which he was told to be seated. CNBC's Jim Cramer weighs in.

Cramer Remix: How to conquer rotations

“Mad Money” host Jim Cramer’s giving investors his insight on how to play rotations.

A dealer handles gaming chips at a baccarat table inside the Venetian Macau resort and casino, operated by Sands China Ltd., a unit of Las Vegas Sands Corp., in Macau, China.

The "Fast Money" traders give four ways to play stocks with great dividends.

Rep. Gowdy to Shkreli's attorney: You wil be seated

Former Turing Pharmaceuticals CEO Martin Shkreli pleads the Fifth Amendment before Congress, and Shkreli's Attorney Benjamin Brafman attempts to address Congress.

Martin Shkreli on the Hill

House Oversight Chairman Jason Chaffetz swears in the panel at the House Oversight Committee hearing on drug price hikes, where former Turing Pharmaceuticals CEO Martin Shkreli is testifying.

Shkreli tweets after pleading Fifth

Former Turing Pharmaceuticals CEO Martin Shkreli has tweeted after being excused from a drug price hearing on Capitol Hill. He says "it is hard to accept that these imbeciles represent the people in our government."

Martin Shkreli, former CEO of Turing Pharmaceuticals, prepares to testify before a House Oversight and Government Reform hearing on Capitol Hill, Feb. 4, 2016.

Martin Shkreli, the former drug company CEO who's come under fire for massive drug price increases, refused to testify Thursday before a congressional committee investigating drug price hikes.

Silent Shkreli smirks in courtroom

While Martin Shkreli said little in court, his expressions and activity on Twitter spoke volumes. CNBC's Meg Tirrell reports, Henry Blodget of Business Insider joins the discussion.

Faber Report: Shari Redstone battling Viacom

CNBC's David Faber reports Viacom CEO Philippe Dauman is likely to be named Viacom Chairman, according to sources.

Drug prices debate

CNBC's Meg Tirrell reports from Capitol Hill, where former Turing Pharmaceuticals CEO Martin Shkreli's invoked the Fifth Amendment at a drug price hike hearing.

Attorney: No disrespect, just 'nervous energy' by Shkreli

Former Turing Pharmaceuticals CEO Martin Shkreli's Attorney Benjamin Brafman speaks to the press after Shkreli was excused from a House panel hearing.

Cummings to Shkreli: You could change the system, are you listening?

Rep. Elijah Cummings presses former Turing Pharmaceuticals CEO Martin Shkreli on Capitol Hill, as he testifies before the House Oversight Committee hearing on drug price hikes, invoking the Fifth Amendment.

Martin Shkreli, former CEO of Turing Pharmaceuticals LLC, is sworn in before a House Oversight and Government Reform hearing on "Developments in the Prescription Drug Market Oversight" on Capitol Hill in Washington February 4, 2016.

Former Turing Pharmaceuticals CEO Martin Shkreli testifies before the House Oversight Committee hearing on drug price hikes, invoking the Fifth Amendment.

Jim Cramer: Drug price hearing 'not for show'

The "Squawk on the Street" crew discuss the House Oversight Committee hearing on drug price hikes, where former Turing Pharmaceuticals CEO Martin Shkreli, and Valeant Pharmaceuticals interim CEO Howard Schiller are testifying.

Google search engine on mobile phone.

Google's head of its AI unit will takeover search. Will this shape a new way to search the entire web?

Can markets predict recessions?

CNBC's Steve Liesman takes a look at which bear markets leads to recession and which don't.

Futures point to higher market open

Market volatility continues to be in evidence on Wall Street, with a late-day Wednesday comeback turning a triple-digit Dow loss into a triple-digit gain.

Sumner Redstone resigns as CBS executive chairman

It's the end of an era as media mogul Sumner Redstone steps down at CBC and CEO Les Moonves takes the reigns, reports CNBC's Landon Dowdy.

Are the markets overly bearish?

Robert Tipp of Prudential Fixed Income talks about where to find fixed-income opportunities.

It's time to be a contrarian investor: Amundi's Bradshaw

Myles Bradshaw, head of global aggregate fixed income at Amundi, says the market is pricing too high a probability of a world recession.

Cashin: I think the Russians tried to talk oil price up

CNBC's Mary Thompson and Art Cashin, of UBS, discuss health care and biotech selling, the moves in oil prices and what to expect from markets. "It doesn't make a great deal of sense OPEC would be cutting production," he says.

Cramer: Golden price of oil needed to stay afloat

Mad Money host Jim Cramer says this is the ultimate price that crude will need to hit to keep struggling companies afloat.

Bearish on US Economy

Euro-Pacific Capital's Peter Schiff, says he had warned previously that a Fed hike would cause markets to tumble and the dollar to fall.